Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1/2 1

Status

Completed 203Terminated 71Recruiting 41Active not recruiting 40Withdrawn 19Unknown 11Not yet recruiting 5Approved for marketing 1

Sponsor Class

OTHER 19INDUSTRY 5NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 5Other hematologic neoplasm 1

Conditions

Lymphoma, Follicular 2Lymphoma, B-Cell 2Lymphoma, Large B-Cell, Diffuse 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Injections 36Carboplatin 31Paclitaxel 24Docetaxel 24Capecitabine 24Gemcitabine 22Cisplatin 22pembrolizumab 21Oxaliplatin 21Bevacizumab 20Pemetrexed 18Fluorouracil 13Irinotecan 12Cyclophosphamide 11Nivolumab 8osimertinib 7Topotecan 7Leucovorin 7Dexamethasone 7toripalimab 6tislelizumab 6regorafenib 6lenvatinib 6fludarabine 6Trastuzumab 6Doxorubicin 6Cetuximab 6130-nm albumin-bound paclitaxel 6venetoclax 5Temozolomide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Not yet recruiting × INDUSTRY × Rituximab × Clear all
NCT07562022 2026-05-01

A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma

Sinocelltech Ltd.

Phase 3 Not yet recruiting
93 enrolled
Lymphoid

Lymphoma, Follicular

NCT07520006 2026-04-13

Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

Nurix Therapeutics, Inc.

Phase 1/2 Not yet recruiting
150 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT07477366 2026-03-17

Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma

ImmunityBio, Inc.

Phase 2 Not yet recruiting
20 enrolled
Lymphoid

Lymphoma, B-Cell

NCT07187960 2025-09-23

Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Not yet recruiting
228 enrolled
Lymphoid

Lymphoma, Follicular

NCT05280626 2022-03-15

First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP

Innovent Biologics (Suzhou) Co. Ltd.

Phase 2 Not yet recruiting
100 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡